Unveiling changes in the landscape of patient populations in cancer early drug development

The introduction of new Molecularly Targeted Agents (MTA) has changed the landscape in Early Drug Development (EDD) over the last two decades, leading to an improvement in clinical trial design. Previous Phase 1 (Ph1) studies with cytotoxics focused on safety objectives, only recruiting heavily pre-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Hierro, Cinta, Azaro, Analía, Argilés, Guillem, Elez, Elena, Gómez, Patricia, Carles, Joan, Rodon, Jordi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355170/
https://ncbi.nlm.nih.gov/pubmed/27835915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13258
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi